Carregando...
MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation
Immune evasion is a pivotal event in tumor progression. To eliminate human cancer cells, current immune checkpoint therapy is set to boost CD8(+) T cell–mediated cytotoxicity. However, this action is eventually dependent on the efficient recognition of tumor-specific antigens via T cell receptors. O...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Principais autores: | , , , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773365/ https://ncbi.nlm.nih.gov/pubmed/32990678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI140837 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|